Description

CJC-1295 ipamorelin blend research material combines CJC-1295 (without DAC) and ipamorelin at 5mg + 5mg concentration in a 3ml vial, supplied for laboratory and non-clinical investigation of growth hormone secretagogue research pathways.

What Is the CJC-1295 Ipamorelin Blend

CJC-1295 without DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), while ipamorelin is a selective growth hormone secretagogue receptor (GHS-R) agonist. This CJC-1295 ipamorelin blend research formulation is used by laboratories investigating the combined and complementary effects of GHRH-receptor and GHS-R activation on pulsatile growth-hormone release across in vitro and animal-model research systems.

Research Applications (laboratory / non-clinical research only)

• Animal model research into combined GHRH-receptor and GHS-R activation pathways
• In vitro studies of pulsatile growth-hormone secretion mechanisms
• Preclinical investigation of synergistic secretagogue research pathways
• Comparative research into combined-peptide versus single-peptide endocrine signaling
• Laboratory studies of somatotroph cell response in the anterior pituitary

Quality & Sourcing

This CJC-1295 ipamorelin blend research material is manufactured to high purity standards and verified by HPLC (High-Performance Liquid Chromatography) analysis. Each batch is lyophilized for stability, and a Certificate of Analysis (COA) is available on request confirming peptide identity and purity. Material is intended for use by qualified researchers in controlled laboratory environments only.

Supplied As

Supplied as a lyophilized 5mg + 5mg blend in a 3ml vial, suitable for standard laboratory reconstitution procedures performed by trained personnel for research purposes.

Molecular Characteristics

This blend combines CJC-1295 without DAC, a synthetic GHRH analog, with ipamorelin, a selective growth hormone secretagogue receptor agonist. Because CJC-1295 without DAC lacks the Drug Affinity Complex modification found in the extended-release variant, it is generally reported in the literature to have a shorter functional activity window, which researchers may consider relevant when designing dosing-interval protocols. Both peptides are supplied together as a lyophilized powder to simplify handling for combined-pathway research.

Handling & Storage Considerations

Lyophilized CJC-1295 ipamorelin blend material should be stored in a freezer (-20°C or below), protected from light and moisture, until the researcher is ready to reconstitute the material for a laboratory protocol. Once reconstituted with bacteriostatic water, the solution is generally stored refrigerated (2-8°C) and used within the window supported by internal stability testing. As with other growth-hormone axis peptide blends, repeated freeze-thaw cycles and prolonged room-temperature exposure are generally avoided to preserve research-grade integrity.

Common Research Design Considerations

Laboratories investigating this blend commonly design animal-model studies evaluating combined GHRH-receptor and GHS-R activation, often measuring pulsatile growth-hormone secretion patterns in rodent models. In vitro research frequently uses pituitary cell culture systems to characterize somatotroph cell response to combined-pathway activation. Comparative study designs often examine this blend alongside individually administered CJC-1295 and ipamorelin to characterize whether combined-receptor engagement produces distinct research outcomes relative to single-compound administration.

Frequently Asked Questions

Is this compound stable at room temperature?
Short-term handling at room temperature during active laboratory use is generally acceptable, but frozen storage is recommended between research sessions to preserve peptide integrity.

What purity level should researchers expect?
Material is verified by HPLC analysis at the time of batch testing, with purity data available via the accompanying Certificate of Analysis.

Is a Certificate of Analysis provided?
Yes, a COA is available on request for each batch, confirming identity and purity for research documentation purposes.

Related Compounds

Researchers investigating this blend often also study CJC-1295 without DAC and ipamorelin individually, as well as the CJC-1295 with DAC formulation, to compare extended-release and shorter-acting research approaches within the same laboratory program. This type of comparative panel is common in laboratories seeking to characterize the full spectrum of GHRH and secretagogue receptor pharmacology.

For research use only. Not for human or veterinary use. Not a drug, supplement, or therapeutic product. Not intended to diagnose, treat, cure, or prevent any condition.